Walt Disney, VSee Health, Genprex: Retail Most Bullish On These 3 Stocks Pre-Market

Disney’s fast-pass pilot, VSee Health’s telehealth initiative, and Genprex’s gene therapy trial progress are driving strong interest
Representative image via Vecteezy
Representative image via Vecteezy
Profile Image
Ramakrishnan M·Stocktwits
Updated Jul 02, 2025   |   8:31 PM GMT-04
Share
·
Add us onAdd us on Google

Walt Disney Co. ($DIS)

DIS sentiment and message volume Oct 21 2024.png
DIS sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits

Sentiment on Stocktwits for Walt Disney Co. turned ‘bullish’ (69/100) early Monday before the market opened, compared to a ‘bearish’ sentiment just a day earlier. Disney’s stock has risen nearly 3.5% over the past week. Recent news driving the stock includes Disney’s announcement to pilot a new fast-pass option for rides at its U.S. theme parks, with peak pricing as high as $449. Additionally, Piper Sandler initiated coverage with a ‘Neutral’ rating and a $95 price target. The analyst noted limited upside in the next few quarters due to moderation in Disney’s experiences segment, but remains optimistic about Disney’s broader assets and recent film successes.

VSee Health Inc. ($VSEE)

GNPX sentiment and message volume Oct 21 2024.png
VSEE sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits

VSee Health scored an ‘extremely bullish’ (97/100) sentiment on Stocktwits pre-market Monday, following a nearly 36% stock gain over the past week. The surge was driven by the announcement of a telehealth initiative in collaboration with Kwajalein Atoll Local Government (KALGOV) and Kwajalein Atoll Sustainability Laboratory (KASL). The project leverages SpaceX’s Starlink technology and VSee’s telemedicine platform to provide virtual healthcare consultations aboard a boat ambulance, aimed at improving access for Marshallese veterans and residents of the Kwajalein Atoll.

Genprex, Inc. ($GNPX)

VSEE sentiment and message volume Oct 21 2024.png
GNPX sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits

Gene therapy company Genprex saw its Stocktwits sentiment hit ‘extremely bullish’ pre-market Monday, after a week of impressive gains over 28%. The optimism followed the company’s announcement that it had advanced to the highest dose group in its Acclaim-3 small cell lung cancer trial for Reqorsa Gene Therapy with Tecentriq, after receiving approval from a safety review committee.
 

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy